In the development of AAV gene therapies, attention typically centers on the clinical question — which disease, which target, which patient population — and on the vector biology — which serotype, which promoter, which transgene. Plasmid quality occupies a less prominent position in most early-stage conversations. It should not. The quality of the plasmid DNA used in AAV manufacturing is one of the most consequential upstream inputs in the entire production process, and plasmid-related quality failures have derailed programs at every stage from clinical manufacturing to lot release.

This article explains what plasmid quality means in the context of gene therapy, which attributes matter most, why each matters, and what the regulatory expectations are for plasmid used in clinical and commercial AAV manufacturing.

What Plasmid Quality Means

Plasmid quality encompasses several distinct attributes: the proportion of plasmid in its supercoiled form, the level of endotoxin contamination, the amount of residual host cell DNA, the presence or absence of sequence errors, and the concentration and purity of the final plasmid preparation. Each of these attributes affects either the efficiency of the manufacturing process, the quality of the vector product, or both.

Plasmid destined for clinical AAV manufacturing is itself considered a raw material and, depending on its role, potentially a critical starting material. The FDA’s CMC guidance for gene therapy INDs requires characterization of plasmid raw materials, including identity testing, purity assessment, and demonstration of sequence integrity. Sponsors are expected to establish acceptance criteria for each plasmid and to document compliance at each manufacturing campaign. Plasmid that fails to meet these criteria cannot be used in GMP production — and because plasmid synthesis and production has its own manufacturing lead time, quality failures at this stage create program delays that compound downstream.

Supercoiled Percentage

Plasmid DNA exists in three physical forms: supercoiled (covalently closed circular), relaxed open-circular (nicked), and linear. Of these, the supercoiled form is the most biologically active — it is more efficiently taken up by cells during transfection, more efficiently transcribed once inside the nucleus, and more consistently packaged into viral particles.

In AAV manufacturing, the supercoiled percentage of the plasmid preparation directly affects transfection efficiency and, consequently, vector yield. As the proportion of relaxed or linear forms increases, transfection efficiency declines. Industry practice for clinical-grade plasmid typically targets a supercoiled percentage of 90 percent or greater. Preparations below this threshold may still support production but at reduced efficiency, which affects batch-to-batch consistency — a critical requirement for GMP manufacturing.

Supercoiled content degrades over time and is sensitive to freeze-thaw cycles, extended storage, and suboptimal purification conditions. These variables must be controlled and monitored across the plasmid supply chain to ensure that the material entering the transfection step meets its acceptance criteria.

Endotoxin

Endotoxins are lipopolysaccharide components of the outer membrane of gram-negative bacteria — the same bacteria, such as Escherichia coli, that are used to propagate plasmid DNA at scale. Endotoxins are potent pyrogens: they trigger inflammatory responses in mammalian cells and, at sufficient concentrations, are toxic to producer cell cultures and to patients.

In AAV manufacturing, endotoxin contamination of the plasmid input affects producer cell health during the transfection and production phase, potentially reducing viral yields and introducing variability between batches. More critically, endotoxin in the final drug product is a safety concern requiring demonstration of removal to below regulatory limits during downstream purification.

The FDA and EMA both specify endotoxin limits for parenteral products, and gene therapy products administered intravascularly or intrathecally are subject to particularly stringent limits. Plasmid manufacturing processes are expected to include purification steps — typically column-based chromatography — that demonstrate robust endotoxin clearance, and acceptance criteria for endotoxin content in clinical-grade plasmid are typically set at 10 EU/mg or below.

Residual Host Cell DNA

Plasmid is produced in bacterial host cells, and the plasmid purification process must separate the desired plasmid DNA from the much larger quantity of bacterial chromosomal DNA present in the lysate. Incomplete removal of residual host cell DNA introduces a contaminating nucleic acid burden into the production process.

In the context of AAV manufacturing, residual bacterial DNA represents a potential impurity in the drug substance. It may also complicate downstream analytical testing — PCR-based assays used to measure vector genome titer and identity can be confounded by background nucleic acid if contaminating DNA is present. Regulatory expectations require demonstration that host cell DNA removal is robust and that the final plasmid preparation meets established purity criteria, typically assessed by agarose gel electrophoresis and, for clinical-grade material, by more sensitive quantitative methods.

Sequence Integrity

Plasmid sequence errors — point mutations, deletions, or insertions introduced during synthesis or bacterial amplification — can have consequences that range from negligible to program-ending, depending on where in the plasmid they occur and what they affect.

A sequence error in the therapeutic transgene may alter the encoded protein, reducing potency or introducing an immunogenic sequence not present in the clinical lot used for prior safety studies. A mutation in the promoter or regulatory elements may alter expression levels in ways that are not apparent until clinical samples are analyzed. A sequence error in the ITRs of the transfer plasmid can compromise genome replication and packaging efficiency, reducing vector yield and introducing heterogeneity in the packaged genome population.

For clinical manufacturing, plasmid identity is verified by sequencing at the master cell bank level and on a risk-based frequency during production. Full plasmid sequencing, which was historically resource-intensive, has become more accessible with next-generation sequencing technologies and is increasingly applied to verify sequence integrity of clinical-grade plasmid preparations in their entirety.

GMP Manufacturing of Plasmid

For plasmid used in clinical gene therapy manufacturing, GMP production is required. This means that the plasmid must be manufactured under controlled, documented conditions with defined raw materials, qualified equipment, validated processes, and release testing against pre-established specifications.

GMP plasmid manufacturing is itself a specialized discipline. The production process typically involves inoculation of a bacterial master cell bank, expansion through a defined number of passages, large-scale fermentation, alkaline lysis to release the plasmid, and multi-step purification to achieve the required supercoiled percentage, endotoxin level, and purity. The entire process must be executed under GMP conditions with complete batch records, and the released plasmid must meet all specifications before it can be used in a downstream vector manufacturing campaign.

Manufacturing Platform and Yield Implications

The choice of upstream production platform for AAV — and by extension the demands placed on the plasmid input — has direct economic implications. Cost modeling comparing adherent multi-tray systems, suspension bioreactors, and fixed-bed bioreactors has demonstrated substantial differences in cost per dose at scale. At 200-liter equivalent scale, multi-tray processing achieves approximately $25,000 per dose; suspension culture achieves comparable cost at that scale but improves to approximately $12,000 per dose at 1,000-liter scale. Fixed-bed iCELLis bioreactor systems achieve an initial cost per dose of approximately $21,000 at clinical scale, declining to approximately $8,000 per dose after process optimization.[2]

Fixed-bed systems also demonstrate superior producer cell density — studies comparing fixed-bed reactors to suspension and stirred-tank systems found cell densities 3 to 7 times higher in fixed-bed configurations — contributing to higher per-run vector yields.[3] Transient transfection of suspension-adapted HEK293 cells in wave bioreactor formats has achieved yields exceeding 10¹⁴ viral genomes per liter.[3] In each of these platforms, plasmid quality is an upstream determinant of what these production systems can actually deliver.

Plasmid supply chain failures — delays in GMP production, batch failures at release testing, or supply shortages when multiple programs are competing for limited GMP plasmid capacity — are a recurring source of clinical program delay that is underappreciated at the program planning stage. For sponsors building development timelines, plasmid manufacturing lead time and quality variability should be treated as a critical path item, not a background procurement activity.

The Upstream Quality Imperative

Gene therapy product quality is determined by a cascade of decisions that begins well before the vector is produced. Plasmid quality is the first major link in that chain. A high-quality plasmid preparation — high supercoiled content, low endotoxin, minimal residual host cell DNA, verified sequence integrity — enters the transfection step with the highest probability of producing a consistent, potent, characterizable vector product. A marginal plasmid preparation enters the same step with compounded variability that propagates through titer, full/empty capsid ratio, and ultimately lot release.

In a field where batch sizes are small, doses are high, and the cost of failed batches is substantial, the upstream quality imperative is straightforward: plasmid quality is not a detail to be addressed during manufacturing troubleshooting. It is a foundational input to every aspect of the product that follows.

[2] “Cost Modelling Comparison of Adherent Multi-Trays with Suspension and Fixed-Bed Bioreactors for the Manufacturing of Gene Therapy Products.” Cell and Gene Therapy Insights / Immuno-oncology Insights. 2022. https://www.insights.bio/immuno-oncology-insights/journal/article/15/cost-modelling-comparison-of-adherent-multi-trays-with-suspension-and-fixed-bed-bioreactors-for-the-manufacturing-of-gene-therapy-products

[3] Merten OW, et al. “Large-scale manufacture and characterization of a lentiviral vector produced for clinical ex vivo gene therapy application.” Human Gene Therapy. 2016; updated in: Bioprocess International review of fixed-bed bioreactor performance. https://pmc.ncbi.nlm.nih.gov/articles/PMC4802372/